The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for the treatment of adults and children age 12 years and older who have ...

ADorable-1 randomized 367 pediatric patients after a 2-week topical corticosteroid run-in to weight-based subcutaneous lebrikizumab versus placebo, with week-16 coprimary end points IGA 0/1 and ...

Monthly lebrikizumab maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority (more than 80%) of ADvocate 1 and 2 responders Nearly 87 percent of patients ...

The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older with moderate to severe atopic dermatitis (AD). The FDA approved ...

Please provide your email address to receive an email when new articles are posted on . Both 2-week and monthly dosing of lebrikizumab maintained skin clearance and reduced itch among patients with ...

In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years 75% of patients achieved a high bar of near-complete skin ...

EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals Patients treated with EBGLYSS experienced significant skin ...

Please provide your email address to receive an email when new articles are posted on . “Clinician awareness of atopic comorbidities and the additional impact that these conditions have on patients ...

The introduction of lebrikizumab, a novel monoclonal antibody targeting interleukin-13 for severe atopic dermatitis (AD), was associated with cost savings of approximately €3.3 million over 3 years ...

In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-75) and 44% achieved clear or almost clear skin (IGA 0,1) at Week 16 In key secondary endpoints, 39% of ...

Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority of ADvocate 1 and 2 responders Nearly 87 percent of patients taking EBGLYSS did not ...